BioArctic and Novartis sign an option, collaboration and license agreement using BrainTransporter™ for an upfront payment of USD 30 million plus additional potential milestones and royalties

Contributed by: PR Newswire

Tags

BioArctic-sign

More Like This

BioArctic and Eisai sign research evaluation agreement regarding BAN2802

BrainTransporter™ dramatically improves antibody delivery to the brain

BioArctic announces global license agreement with Bristol Myers Squibb for BioArctic's PyroGlutamate-amyloid-beta antibody program

BioArctic's global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closing

BioArctic's Capital Markets Day 2025 - entering a new era of growth

Regarding rumors of an imminent approval of lecanemab in Great Britain: BioArctic

The drug discovery research for lecanemab awarded the 9th Bioindustry Award by the Japan Bioindustry Association

BioArctic: Latest data on lecanemab to be presented at the 2024 AD/PD™ congress